Roivant Sciences Ltd’s recently made public that its 10% Owner Ramaswamy Vivek unloaded Company’s shares for reported $6.21 million on Jun 04 ’25. In the deal valued at $11.34 per share,547,430 shares were sold. As a result of this transaction, Ramaswamy Vivek now holds 38,627,181 shares worth roughly $427.99 million.
Then, Ramaswamy Vivek sold 200,800 shares, generating $2,246,952 in total proceeds. Upon selling the shares at $11.19, the 10% Owner now owns 38,426,381 shares.
Before that, Ramaswamy Vivek bought 200,800 shares. Roivant Sciences Ltd shares valued at $2,246,311 were divested by the 10% Owner at a price of $11.19 per share.
Wolfe Research initiated its Roivant Sciences Ltd [ROIV] rating to an Outperform in a research note published on February 15, 2024; the price target was $17. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. Deutsche Bank began covering ROIV with “Buy” recommendation on December 12, 2023. Guggenheim started covering the stock on October 17, 2023. It rated ROIV as “a Buy”.
Price Performance Review of ROIV
On Monday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock fall -2.12% to $11.08. Roivant Sciences Ltd shares have fallen nearly -6.34% since the year began. Nevertheless, the stocks have risen 2.31% over the past one year. While a 52-week high of $13.06 was reached on 01/02/25, a 52-week low of $8.73 was recorded on 04/07/25.
Levels Of Support And Resistance For ROIV Stock
The 24-hour chart illustrates a support level at 10.87, which if violated will result in even more drops to 10.67. On the upside, there is a resistance level at 11.37. A further resistance level may holdings at 11.66.
The most recent change occurred on June 08, 2023 when BofA Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $10.50 price target.
